Michael Hayden

Insider profile

Currently holds positions in Aurinia Pharmaceuticals Inc, Ionis Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc

Performance

Overall performance
3.3
Performance over holding periods
3.3
30 days 90 days 120 days
Average return 4% 8.2% 15.1%
Success rate 63% 68% 82%
Transactions
13 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Director Aurinia Pharmaceuticals Inc Feb. 22, 2018 -
Director Ionis Pharmaceuticals, Inc. Sept. 24, 2018 -
Independent Director Xenon Pharmaceuticals Inc Jan. 1, 1996 -
President - Global Research and Development, Chief Scientific Officer Teva Pharmaceutical Industries Limited May 8, 2012 - Dec. 31, 2017
Michael Hayden's trades of Abcellera Biologics Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Purchase
Price
437.63
Quantity 17,766 -25.8%
Value US$3,480,360
Transaction date
Purchase
Price
301.17
Quantity 50,145 -17.0%
Value US$553,574
Transaction date
Purchase
Price
36.23
Quantity 2,500 +7.6%
Value US$90,583
Transaction date
Purchase
Price
36.20
Quantity 2,500 +8.3%
Value US$90,496
US 89Bio Inc (ETNB)
Transaction date
Purchase
Price
16.15
Quantity 61,538 New position
Value US$993,839
US 89Bio Inc (ETNB)
Transaction date
Purchase
Price
2.67
Quantity 10,000 +10.6%
Value US$26,700
US 89Bio Inc (ETNB)
Transaction date
Purchase
Price
3.48
Quantity 10,000 +11.9%
Value US$34,750
US 89Bio Inc (ETNB)
Transaction date
Purchase
Price
3.62
Quantity 6,250 +8.0%
Value US$22,625
Transaction date
Purchase
Price
20.00
Quantity 73,665 +165.2%
Value US$1,473,300
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-24 2026-08-24
B Purchase
17,766 -25.8%
437.63
US$3,480,360 		17,766 -25.8% 437.63 US$3,480,360
2026-08-14 2026-08-12
B Purchase
50,145 -17.0%
301.17
US$553,574 		50,145 -17.0% 301.17 US$553,574
2026-07-31 2026-07-31
B Purchase
39,761 -17.3%
143.88
US$1,490,099 		39,761 -17.3% 143.88 US$1,490,099
2026-07-31 2026-07-30
B Purchase
15,000 +375.0%
53.38
US$800,700 		15,000 +375.0% 53.38 US$800,700
2025-05-02 2025-05-01
B Purchase
15,000 +42.6%
31.86
US$477,900 		15,000 +42.6% 31.86 US$477,900
2024-12-26 2024-12-23
B Purchase
2,500 +7.6%
36.23
US$90,583 		2,500 +7.6% 36.23 US$90,583
2024-12-26 2024-12-23
B Purchase
2,500 +8.3%
36.20
US$90,496 		2,500 +8.3% 36.20 US$90,496
2023-09-26 2023-09-22
B Purchase
20,000 +1.5%
4.91
US$98,200 		20,000 +1.5% 4.91 US$98,200
2023-08-09 2023-08-08
B Purchase
30,000 +2.4%
5.90
US$177,000 		30,000 +2.4% 5.90 US$177,000
2023-03-30 2023-03-28
US 89Bio Inc (ETNB)
B Purchase
61,538 New position
16.15
US$993,839 		61,538 New position 16.15 US$993,839
2023-03-30 2022-04-25
US 89Bio Inc (ETNB)
B Purchase
10,000 +10.6%
2.67
US$26,700 		10,000 +10.6% 2.67 US$26,700
2023-03-30 2022-04-07
US 89Bio Inc (ETNB)
B Purchase
10,000 +11.9%
3.48
US$34,750 		10,000 +11.9% 3.48 US$34,750
2023-03-30 2022-03-30
US 89Bio Inc (ETNB)
B Purchase
6,250 +8.0%
3.62
US$22,625 		6,250 +8.0% 3.62 US$22,625
2021-06-22 2021-06-22
S Sale
100,000 -9.1%
25.50
US$2,550,000 		100,000 -9.1% 25.50 US$2,550,000
2020-12-17 2020-12-15
B Purchase
73,665 +165.2%
20.00
US$1,473,300 		73,665 +165.2% 20.00 US$1,473,300